Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RAPP

Rapport Therapeutics Inc

Apr 17 • 04:00PM ET

39.71

+0.17 0.43 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BLUE REGN SAGE NBIX ACAD MRNA CRSP EDIT

| Held by: VTI IWM VXF IWN IBB XPH SCHA VTWO IHE IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.87	Insider Own	38.70%	Shs Outstand	47.77M	Perf Week	16.21%
Market Cap	1.90B	Forward P/E	-	EPS next Y	-4.21	Insider Trans	-0.72%	Shs Float	29.30M	Perf Month	49.96%
Enterprise Value	1.42B	PEG	-	EPS next Q	-0.62	Inst Own	73.02%	Short Float	13.14%	Perf Quarter	47.84%
Income	-111.48M	P/S	-	EPS this Y	-17.84%	Inst Trans	4.49%	Short Ratio	11.87	Perf Half Y	54.03%
Sales	0.00M	P/B	3.91	EPS next Y	-24.83%	ROA	-26.95%	Short Interest	3.85M	Perf YTD	30.88%
Book/sh	10.15	P/C	3.87	EPS next 5Y	-18.28%	ROE	-28.22%	52W High	42.27 -6.05%	Perf Year	291.23%
Cash/sh	10.27	P/FCF	-	EPS past 3/5Y	-114.24% -	ROIC	-22.60%	52W Low	7.73 413.71%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.11% 6.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-33.82%	Oper. Margin	-	ATR (14)	2.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	26.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	79.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	26.17	EPS Q/Q	-31.58%	SMA20	22.58%	Beta	1.51	Target Price	53.60
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	31.72%	Rel Volume	5.14	Prev Close	39.54
Employees	84	LT Debt/Eq	0.02	Earnings	Mar 10 BMO	SMA200	57.66%	Avg Volume	324.18K	Price	39.71
IPO	Jun 07, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.27% -	Trades		Volume	1,666,468	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Initiated	Raymond James	Strong Buy	$66
Feb-02-26	Initiated	Wells Fargo	Overweight	$43
Nov-19-25	Initiated	BTIG Research	Buy	$47
Sep-16-25	Initiated	Truist	Buy	$44
Aug-06-25	Initiated	H.C. Wainwright	Buy	$31
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Apr-01-26 07:00AM	Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-10-26 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-26 09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
07:00AM	Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China (GlobeNewswire)
Feb-24-26 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Jan-07-26 07:00AM	Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline (GlobeNewswire) +8.89%
Dec-18-25 07:00AM	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 12:00PM	Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know (Zacks)
Dec-05-25 09:00AM	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures (GlobeNewswire)
Nov-28-25 09:55AM	Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? (Zacks)
Nov-25-25 07:00AM	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-12-25 09:55AM	Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet (Zacks)
Nov-06-25 07:00AM	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Nov-05-25 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-30-25 11:49AM	JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success (Insider Monkey) +6.19%
11:13AM	Loading…
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 04:05PM	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
Sep-09-25 09:17PM	Rapport Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.93% -20.09%
Sep-08-25 04:08PM	Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily) +119.15%
04:05PM	Rapport Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:45AM	Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily)
09:28AM	Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year (Benzinga)
06:00AM	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures (GlobeNewswire)
Sep-05-25 04:05PM	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 (GlobeNewswire) -6.45%
Aug-13-25 08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
Aug-07-25 07:00AM	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update (GlobeNewswire) +5.48%
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
07:00AM	Loading…
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KRISHNASWAMY YELESWARAM	Officer	Apr 17 '26	Proposed Sale	39.54	20,225	799,696		Apr 17 04:37 PM
Third Rock Ventures V, L.P.	10% Owner	Apr 17 '26	Proposed Sale	40.32	426,005	17,175,116		Apr 17 04:25 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 14 '26	Sale	35.08	10,200	357,797	266,651	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 13 '26	Sale	34.97	9,165	320,537	276,851	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 10 '26	Sale	34.98	500	17,490	286,016	Apr 14 04:13 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 13 '26	Proposed Sale	34.17	19,365	661,702		Apr 13 04:37 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 10 '26	Proposed Sale	34.22	500	17,110		Apr 10 04:34 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 08 '26	Sale	34.90	360	12,564	286,516	Apr 09 04:30 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 08 '26	Proposed Sale	33.49	360	12,056		Apr 08 05:35 PM
Gault Cheryl	Chief Operating Officer	Mar 30 '26	Sale	28.19	10,000	281,857	159,914	Mar 31 04:27 PM
CHERYL GAULT	Officer	Mar 30 '26	Proposed Sale	27.84	10,000	278,400		Mar 30 05:31 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Mar 25 '26	Sale	29.99	10,115	303,355	286,876	Mar 26 04:41 PM
KRISHNASWAMY YELESWARAM	Officer	Mar 25 '26	Proposed Sale	28.25	10,115	285,749		Mar 25 04:22 PM
Gault Cheryl	Chief Operating Officer	Mar 05 '26	Sale	28.93	2,014	58,265	169,914	Mar 09 04:07 PM
Gault Cheryl	Officer	Mar 05 '26	Proposed Sale	28.92	2,014	58,236		Mar 05 05:54 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.34	5,833	171,161	556,247	Feb 19 07:06 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.36	5,083	149,212	20,729	Feb 19 07:06 PM
Bredt David	Chief Scientific Officer	Feb 19 '26	Option Exercise	1.80	6,000	10,800	393,075	Feb 19 07:05 PM
Bredt David	Chief Scientific Officer	Feb 17 '26	Sale	29.02	8,500	246,655	387,075	Feb 19 07:05 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.12	5,833	152,333	562,080	Jan 22 07:00 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.11	5,083	132,737	25,812	Jan 22 07:00 PM
Bredt David	Chief Scientific Officer	Jan 15 '26	Sale	26.84	8,500	228,132	395,575	Jan 16 04:06 PM
DAVID BREDT	Officer	Jan 15 '26	Proposed Sale	27.42	17,000	466,140		Jan 15 04:28 PM
Bredt David	Chief Scientific Officer	Dec 31 '25	Sale	30.05	6,567	197,338	404,075	Jan 05 04:20 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Dec 31 '25	Sale	30.05	2,840	85,342	296,991	Jan 05 04:19 PM
DAVID BREDT	Officer	Jan 02 '26	Proposed Sale	30.05	6,567	197,338		Jan 02 08:20 PM
Krishnaswamy Yeleswaram	Officer	Jan 02 '26	Proposed Sale	30.05	2,840	85,343		Jan 02 08:17 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.64	5,833	172,877	567,913	Dec 18 04:11 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.63	5,083	150,632	30,895	Dec 18 04:11 PM
THE DOROTHY CEESAY IRREVOCABLE	Director	Dec 17 '25	Proposed Sale	30.76	15,249	469,059		Dec 17 04:28 PM
ABRAHAM CEESAY	Director	Dec 17 '25	Proposed Sale	30.76	17,499	538,269		Dec 17 04:25 PM
Bredt David	Chief Scientific Officer	Dec 15 '25	Sale	30.02	8,500	255,130	392,642	Dec 16 05:07 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Option Exercise	1.80	5,000	9,000	176,928	Dec 01 04:17 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Sale	30.10	5,000	150,486	171,928	Dec 01 04:17 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.19	5,833	146,931	573,746	Nov 18 04:27 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.20	5,083	128,116	35,978	Nov 18 04:27 PM
Bredt David	Chief Scientific Officer	Nov 17 '25	Sale	25.19	8,500	214,091	401,142	Nov 18 04:24 PM
Bredt David	Chief Scientific Officer	Oct 15 '25	Sale	25.79	8,500	219,196	409,642	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,833	150,541	579,579	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,083	131,189	41,061	Oct 16 04:30 PM
DAVID BREDT	Officer	Oct 15 '25	Proposed Sale	24.88	25,500	634,440		Oct 15 04:26 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	40,835	1,074,725	585,412	Sep 19 04:05 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	35,585	936,472	46,144	Sep 19 04:05 PM
ABRAHAM CEESAY	Director	Sep 17 '25	Proposed Sale	26.19	52,501	1,375,001		Sep 17 04:28 PM
THE DOROTHY CEESAY IRREV TRUST	Director	Sep 17 '25	Proposed Sale	26.19	45,751	1,198,219		Sep 17 04:26 PM
Bredt David	Chief Scientific Officer	Sep 15 '25	Sale	24.19	8,500	205,649	418,142	Sep 17 04:15 PM
Huber Reid M	Director	Sep 12 '25	Buy	24.48	20,400	499,374	20,400	Sep 15 04:05 PM
PAUL STEVEN M	Director	Sep 12 '25	Buy	24.65	41,666	1,027,111	41,666	Sep 15 04:05 PM
Young Wendy B.	Director	Sep 11 '25	Buy	22.60	3,500	79,100	9,500	Sep 11 06:13 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Option Exercise	1.80	5,000	9,000	176,928	Sep 10 04:15 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Sale	38.33	5,000	191,650	171,928	Sep 10 04:15 PM
CHERYL GAULT	Officer	Sep 08 '25	Proposed Sale	14.36	10,000	143,600		Sep 08 04:24 PM
Bredt David	Chief Scientific Officer	Aug 15 '25	Sale	15.00	8,500	127,466	426,642	Aug 18 05:14 PM
Bredt David	Chief Scientific Officer	Jul 15 '25	Sale	14.00	8,500	118,962	435,142	Jul 16 04:14 PM
Bredt David	Chief Scientific Officer	Jun 16 '25	Sale	11.00	8,500	93,522	443,642	Jun 18 04:15 PM
DAVID BREDT	Officer	Jun 16 '25	Proposed Sale	11.19	34,000	380,460		Jun 16 04:24 PM
Bredt David	Chief Scientific Officer	May 15 '25	Sale	9.56	8,500	81,262	452,142	May 19 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc

Upgrade your Finviz experience